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Swine influenza viruses (SIV) have been shown to sporadically infect humans and are infrequently identified
by the Influenza Division of the Centers for Disease Control and Prevention (CDC) after being received as
unsubtypeable influenza A virus samples. Real-time reverse transcriptase PCR (rRT-PCR) procedures for
detection and characterization of North American lineage (N. Am) SIV were developed and implemented at
CDC for rapid identification of specimens from cases of suspected infections with SIV. These procedures were
utilized in April 2009 for detection of human cases of 2009 A (H1N1) pandemic (pdm) influenza virus infection.
Based on genetic sequence data derived from the first two viruses investigated, the previously developed
rRT-PCR procedures were optimized to create the CDC rRT-PCR Swine Flu Panel for detection of the 2009 A
(H1N1) pdm influenza virus. The analytical sensitivity of the CDC rRT-PCR Swine Flu Panel was shown to be
5 copies of RNA per reaction and 101.30.7 50% infectious doses (ID50) per reaction for cultured viruses.
Cross-reactivity was not observed when testing human clinical specimens or cultured viruses that were positive
for human seasonal A (H1N1, H3N2) and B influenza viruses. The CDC rRT-PCR Swine Flu Panel was
distributed to public health laboratories in the United States and internationally from April 2009 until June
2010. The CDC rRT-PCR Swine Flu Panel served as an effective tool for timely and specific detection of 2009
A (H1N1) pdm influenza viruses and facilitated subsequent public health response implementation.
Swine influenza is a common contagious respiratory disease
of pigs caused by influenza A viruses (6, 11). The first swine
influenza virus (SIV), also referred to as classical SIV H1N1
virus, was isolated in the United States in 1930 and circulated
in pigs for at least 60 years (22, 24). From 1997 to 1998,
triple-reassortant SIV (tr-SIV) H1N1, H1N2, H3N2, and
H2N3 subtypes containing gene segments from human, avian,
and swine influenza viruses were found to be circulating in
North American (N. Am) swine populations (13, 14, 29, 33).
Genetic analysis showed that, in particular, the nucleoprotein
(NP) gene of tr-SIVs was inherited from classical SIV, that the
origins of the hemagglutinin (HA) and neuraminidase (NA)
genes differed, and that those genes were most closely related
to genes of classical SIV (H1N1), and recently isolated human
(H1N2 and H3N2) or avian (H2N3) viruses (17, 30, 33) (Fig.
1). These findings provide compelling evidence that tr-SIVs
have an enhanced ability to acquire novel surface glycopro-
teins, thus causing public health concerns because of their
potential pandemic threat (26).
Although SIVs regularly cause illness in pigs and do not
commonly infect humans, sporadic cases of human infection
have been reported in many countries (10, 18, 20, 23, 31).
Between 1990 and 2010, a total of 26 cases of human infections
with SIVs were detected in the United States, most of which
were isolated single cases of infection, with a history of direct
or indirect exposure to pigs prior to onset of illness. In two
cases, limited human-to-human transmission could not be ex-
cluded (3, 4, 23). Because sporadic human infections of SIVs
were detected through passive surveillance for human influ-
enza, for which only a small subset of influenza A-positive
samples are comprehensively analyzed, it was unclear how
many human cases of SIV were occurring undetected. Thus,
real-time reverse transcriptase PCR (rRT-PCR) procedures
were designed and optimized at the Influenza Division of the
Centers for Disease Control and Prevention (CDC) in 2008 to
allow for rapid, sensitive, and specific detection of these cases
(25).
In April 2009, the first human cases of 2009 A (H1N1)
pandemic (pdm) influenza were detected using the CDC rRT-
PCR procedures originally designed to detect human cases of
tr-SIV infection (12, 25). This novel influenza virus, first found
in the United States and Mexico (2, 7, 9, 19), had never been
previously isolated. Complete genome analysis determined
that the 2009 A (H1N1) pdm influenza virus inherited its genes
from an N. Am tr-SIV H1N1 virus and a Eurasian “avian-like”
SIV (2, 7, 9, 19) (Fig. 1).
This paper describes the development and analytical perfor-
mance of the CDC rRT-PCR Swine Flu Panel, based on the
initial CDC rRT-PCR procedures for detection of N. Am tr-
SIV. In response to the influenza pandemic of 2009, the CDC
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rRT-PCR Swine Flu Panel and required reagents and supplies
were distributed globally and implemented for rapid testing of
specimens for the 2009 A (H1N1) pdm influenza virus.
MATERIALS AND METHODS
Influenza viruses and clinical specimens. Influenza viruses tested in this study
were grown to high titers in either Madin-Darby canine kidney (MDCK) cells or
embryonated chicken eggs (ECE) (27). Infectious virus in culture supernatants
or allantoic fluids was measured by determination of the number of 50% tissue
culture infectious doses per milliliter (TCID50/ml) or the number of 50% egg
infectious doses per milliliter (EID50/ml), respectively (21).
Clinical specimens (nasal washes, nasal swabs, nasopharyngeal swabs, throat
swabs, and lower respiratory tract specimens) included in this study were re-
ceived from U.S. state and local public health laboratories as well as foreign
laboratories between April 2009 and June 2010.
RNA extraction. Viral RNA was extracted from 100 l of virus isolates or
clinical specimens and eluted in 100-l volumes by the use of a MagNA Pure
Compact RNA isolation kit (RNA_Tissue_V3_1 protocol) and a MagNA Pure
Compact instrument (Roche Applied Science), according to the manufacturer’s
instructions.
CDC rRT-PCR Swine Flu Panel primers and probes. The CDC rRT-PCR
Swine Flu Panel includes four oligonucleotide primer and probe sets (universal
influenza A [InfA], swine influenza A [swInfA], swine H1 [swH1], and RNase P
[RP]) designed for the detection and characterization of 2009 A (H1N1) influ-
enza viruses in human specimens. The assay was designed such that all three
assays (InfA, swInfA, and swH1) must be positive to indicate detection of N. Am
SIV H1N1 or 2009 A (H1N1) pdm virus. A result where only one or two of the
three assays are positive would be inconclusive and would require further char-
acterization. The InfA assay was designed for universal detection of the matrix
(M) gene of all influenza A viruses. The swInfA assay was designed for universal
detection of the NP gene of all N. Am SIV subtypes and for differentiation of the
SIV subtypes from those of human seasonal influenza A (H1N1) and A (H3N2)
viruses. The swH1 assay was designed to specifically detect the HA gene of
classical SIV or N. Am tr-SIV bearing classical H1 subtype as well as 2009 A
(H1N1) pdm influenza virus and differentiate them from those of human sea-
sonal influenza A (H1N1). The RP assay detects the human RNase P gene and
is used with human clinical specimens to measure the quality of the specimens as
well as to indicate that nucleic acid was extracted adequately from the clinical
specimen (8).
Oligonucleotide primers and probes were designed based on available nucle-
otide sequence data from the GenBank database of the National Center for
Biotechnology Information (NCBI), NIH, the influenza sequence database of
Los Alamos National Laboratories (LANL), and the Global Initiative on Sharing
Avian Influenza Data (GISAID). Nucleotide BLAST search (NCBI) analysis was
used to verify primer and probe sequence specificity and avoid potential non-
specific reactivity. The primers and probes were designed to have annealing
temperatures of approximately 60°C and 70°C, respectively, using PrimerExpress
3.0 software (Applied Biosystems, Foster City, CA). Dual-labeled hydrolysis
probes were labeled at the 5 end with the reporter dye 6-carboxyfluorescein
(FAM) and quenched with Blackhole Quencher 1 (BHQ1) either at the 3 end
or internally at a modified “T” residue with Spacer3 (3-Sp3) at the 3 end to
prevent probe extension by Taq polymerase (Biosearch Technologies, Inc.).
Primers and dually labeled TaqMan hydrolysis probes were synthesized by Bio-
search Technologies, Inc. (Novato, CA) (see Table S1 in the supplemental
material) (32).
rRT-PCR conditions. Reaction conditions for rRT-PCR were based on the
Food and Drug Administration (FDA)-cleared CDC Human Influenza Virus
Real-time RT-PCR Detection and Characterization Panel (CDC rRT-PCR Flu
Panel) (1). The CDC rRT-PCR Flu Panel contains the same primer and probe
set for detection of the influenza A virus matrix gene as the CDC rRT-PCR
Swine Flu Panel. In order to determine the optimal annealing and extension
temperatures, thermal gradient analysis was performed in triplicate using the
Bio-Rad CFX96 system and extracted RNA from 2009 A (H1N1) pdm influenza
virus strain A/California/07/2009 (Table 1; see also Fig. S1 in the supplemental
material). Thermocycling rRT-PCR conditions were as follows: 50°C for 30 min,
Taq activation for 2 min at 95°C, and 45 cycles of 95°C for 15 s and an annealing-
extension step with temperatures ranging from 50 to 65°C for 30 s. All three
assays showed comparable levels of performance, with annealing temperatures
ranging from 50°C to 60°C. The final reaction annealing temperature was set to
55°C, which is 5°C below the maximum optimal annealing temperature (60°C)
used to accommodate potential nucleotide mismatches in the primer-probe re-
gions due to virus evolution.
PCR parameters of the CDC rRT-PCR Swine Flu Panel were optimized using
Invitrogen SuperScript III Platinum One-Step quantitative RT-PCR kits (Life
Technologies) and Stratagene Mx3005P, Bio-Rad CFX96, and Applied Biosys-
tems (AB) 7500 Fast Dx real-time PCR systems. All rRT-PCRs were performed
at a total reaction volume of 25 l. Final primer and probe reaction concentra-
tions were 0.8 M and 0.2 M, respectively. All analytical performance data and
clinical specimen data were collected using an AB 7500 Fast Dx Real-Time PCR
instrument.
RESULTS
CDC rRT-PCR Swine Flu Panel reaction efficiencies. Reac-
tion efficiencies of the primer and probe sets of InfA, swInfA,
and swH1 assays were determined by testing a 5-fold serial
FIG. 1. Schematic diagram representing the genotypes of N. Am tr-SIV H1N1, H1N2, and H3N2 subtypes and 2009 A (H1N1) pdm influenza
viruses. Gray, yellow, green, and pink gene segments represent genes originating from human seasonal, avian, classical swine, and Eurasian swine
influenza viruses, respectively.
TABLE 1. Determination of optimal annealing temperature
Annealing
temperature (°C)
CT value for indicated assaya
InfA swInfA swH1
50.0 18.92  0.06 19.79  0.50 21.34  0.03
51.0 18.89  0.10 19.49  0.39 21.35  0.02
53.0 18.66  0.26 20.09  0.61 21.40  0.02
55.9 18.72  0.18 19.29  0.19 21.76  0.02
59.5 18.77  0.08 19.36  0.27 22.35  0.06
62.5 18.84  0.02 19.26  0.06 22.35  0.41
64.1 18.76  0.14 19.09  0.03 25.86  0.20
65.0 18.65  0.26 19.41  0.05 29.48  0.25
a Values represent mean CT values  SD (n  3) of the results with annealing
temperature ranging from 50°C to 65°C. Thermal gradient analysis was per-
formed using viral RNA of 2009 A (H1N1) pdm influenza virus (A/California/
07/2009) and a Bio-Rad CFX96 real-time PCR detection system.
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dilution series of viral RNA of 2009 A (H1N1) pdm influenza
virus strain A/California/07/2009 in duplicate. The resulting
threshold cycle (CT) values were plotted versus relative RNA
concentration values, and linear regression analysis was ap-
plied to determine the slopes. The reaction efficiencies of the
InfA, swInfA, and swH1 assays were thereby estimated to be
95.7% (R2  0.996), 94.3% (R2  0.976), and 99.5% (R2 
0.994), respectively (see Fig. S2 in the supplemental material).
Analytical sensitivity. The limits of detection (LoD) of the
InfA, swInfA, and swH1 assays were determined by analyzing
a 10-fold dilution series of grown influenza viruses [classical
SIV H1N1 strain A/Maryland/12/1991 and two 2009 A (H1N1)
pdm influenza virus strains, A/California/04/2009 and A/Cali-
fornia/07/2009]. A 10-fold dilution series was tested in tripli-
cate for each extracted virus strain (Table 2). The LoD of the
CDC rRT-PCR Swine Flu Panel was determined according to
the lowest concentration at which all three assays (InfA,
swInfA, and swH1) gave positive results. The LoD was deter-
mined to be a virus concentration of 101.01.6 ID50/ml for the
three viruses tested. This correlates to 101.30.7 ID50 per
reaction (5.0 l/reaction). Similarly, quantified synthetic RNA
of 2009 A (H1N1) pdm influenza virus (Armored RNA Quant;
AsuraGen, Inc.) was tested in duplicate (Table 3) to determine
the minimum RNA copy number detectable by the assay. The
LoD of the InfA, swInfA, and swH1 assays was found to be 5
copies of RNA per reaction. The cutoff CT value for the CDC
Swine Flu Panel was determined to be 38 for domestic hu-
man diagnostic testing purposes under conditions of FDA
Emergency Use Authorization in the United States. This cutoff
value is based upon data from LoD analysis that are consistent
with the cutoff value of 38 previously established for the
CDC rRT-PCR Flu Panel (1).
Analytical specificity and inclusivity. Assay specificity was
demonstrated by testing 10 2009 A (H1N1) pdm influenza
viruses, propagated in either MDCK cell culture or ECE. Vi-
ruses were diluted to approximately 10-fold above the limit of
detection of the assay (approximately 102 to 103 ID50/ml), and
the extracted RNA was tested in triplicate. As expected, all 10
viruses tested positive in the InfA, swInfA, and swH1 assays at
low virus concentrations (Table 4).
To assess the performance of the CDC rRT-PCR Swine Flu
Panel with various SIVs isolated from pigs and humans, ex-
tracted RNAs from cultured SIVs were tested (Table 5). Two
classical SIV H1N1 subtype viruses and five N. Am tr-SIV
H1N1 subtype viruses gave positive results in the InfA, swInfA,
and swH1 assays. One N. Am tr-H1N2 subtype virus (whose
HA originated from a human influenza virus) and one N. Am
tr-H3N2 subtype virus were positive in the InfA and swInfA
assays and negative in the swH1 assay. One Eurasian-lineage
SIV H1N1 subtype virus was InfA positive and swInfA and
swH1 negative. All test results were 100% concordant with the
expected results.
Analytical specificity and exclusivity. In order to demon-
strate the absence of cross-reactivity with other common hu-
man respiratory pathogens, exclusivity testing was performed
TABLE 2. Assay limit of detection (LoD) with 2009 A (H1N1)







104.4 // // //
103.4 // // //
102.4 // // //
101.4 // // // 101.4
100.4 // // //
100.4 // // //
A/California/04/2009b
104.6 // // //
103.6 // // //
102.6 // // //
101.6 // // // 101.6
100.6 // // //
100.6 // // //
101.6 // // //
A/Maryland/12/1991a
105.0 // // //
104.0 // // //
103.0 // // //
102.0 // // //
101.0 // // // 101.0
100.0 // // //
101.0 // // //
a Data represent EID50/ml values.
b Data represent TCID50/ml values.
c , positive rRT-PCR result; , negative rRT-PCR result.




CT values for duplicate assays
InfA swInfA swH1
500 31.30/31.71 33.17/33.56 33.14/33.45
50 34.54/34.49 37.44/37.46 37.05/37.12
5 37.88/38.04 39.54/40.98 39.06/40.32
1 / / /
0.1 / / /
a The RNA material 	Armored RNA Quant Flu A (H1N1) 2009; received
from AsuraGen, Inc.
 included HA, NP, and M gene region sequences derived
from 2009 A (H1N1) pdm influenza virus. , negative rRT-PCR results.
TABLE 4. Analytical specificity (inclusivity) testing with 2009 A
(H1N1) pdm influenza viruses (n  3)
Influenza virus Infectioustitera
Avg CT value for
indicated assayb
InfA swInfA swH1
A/Mexico/4108/2009 2.5c 33.46 34.88 32.89
A/California/08/2009 2.2c 29.75 30.59 28.93
A/California/07/2009 2.4c 34.16 35.05 33.48
A/California/04/2009 1.9d 32.26 32.35 32.05
A/Texas/48/2009 2.0d 32.20 32.01 32.23
A/Washington/29/2009 2.5d 30.58 31.21 30.76
A/South Carolina/18/2009 2.6d 25.44 28.77 27.45
A/New York/18/2009 2.7c 27.95 30.55 29.83
A/England/195/2009 2.0d 26.92 29.74 30.66
A/North Carolina/39/2009 2.7d 27.23 31.32 29.38
a Values represent adjusted virus titers after dilution of cultured viruses.
b Data represent mean CT values (n  3).
c Data represent EID50/ml values.
d Data represent TCID50/ml values.
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by examining 10 contemporary human seasonal influenza A
(H1N1), A (H3N2), and B viruses grown to high virus titers in
either ECE or MDCK cells (see Table S2 in the supplemental
material). All influenza A viruses were InfA positive and
swInfA and swH1 negative, as expected. All influenza B viruses
were negative with all three assays. Analytical specificity was
further demonstrated by testing 34 noninfluenza virus strains
and bacterial organisms commonly present in the nasopharynx
region of the human respiratory tract. Cross-reactivity was not
observed with any of the noninfluenza organisms tested at high
titers (see Table S3 in the supplemental material). Extracted
RNA from non-SIV animal influenza viruses were also tested
at high virus titers (see Table S4 in the supplemental material).
As expected, all non-SIV animal influenza viruses tested were
InfA positive and swH1 negative, although some viruses were
positive in the swInfA assay. However, as not all three assays
were positive for any non-SIV animal influenza virus, such
results would be considered inconclusive and require further
testing.
Monitoring the clinical performance of the CDC rRT-PCR
Swine Flu Panel. A set of 688 clinical specimens received by
the CDC from May 2009 through June 2010 from U.S. public
health and international laboratories, including 131 seasonal
influenza A (H1N1), 360 seasonal influenza A (H3N2), 92
influenza B, and 105 influenza A- and B-negative samples, was
used for monitoring clinical performance. All specimens from
the set were swInfA and swH1 negative when the CDC rRT-
PCR Swine Flu Panel was used.
A total of 607,344 respiratory specimens were tested for the
presence of influenza virus by U.S. public health laboratories
from 2 May 2009 through 6 February 2010 (12). In order to
monitor the performance of the CDC rRT-PCR Swine Flu
Panel, U.S. public health laboratories were instructed to send
human clinical specimens (nasal washes, nasal swabs, nasopha-
ryngeal swabs, throat swabs, and lower respiratory tract spec-
imens) with inconclusive test results to the CDC Influenza
Division for further testing and characterization (Fig. 2, CDC
Influenza Division test results). Of 281 clinical specimens re-
ceived due to inconclusive results, 160 specimens (59%) had
InfA assay CT values higher than 30 when tested at CDC,
indicating low viral concentrations near the limit of detection
of the assay (average InfA CT value  34.0, standard deviation
[SD]  2.2). Of those 160 specimens tested at CDC, 86 (54%)
were found to be positive for 2009 A (H1N1) pdm influenza
virus, 26 were inconclusive, 2 were invalid (influenza virus and
RP markers all tested negative), and 46 were negative. The
remaining 121 specimens received due to inconclusive results
with InfA testing had CT values  30, indicating that virus
titers in these specimens were well above the limit of detection
of the assay. Of those 121 speciments, 103 (85%) were found
to be positive for 2009 A (H1N1) pdm influenza virus by
rRT-PCR or genetic sequence characterization. Eighteen spec-
imens received due to inconclusive results were positive for
multiple influenza viruses, suggesting coinfection with two or
more influenza virus strains. Upon further genetic character-
ization, 12 of those 18 specimens contained seasonal trivalent
live attenuated influenza virus vaccine (LAIV) and 6 were
found to be positive for 2009 A (H1N1) pdm LAIV. Specimens
containing 2009 A (H1N1) pdm LAIV that are tested using the
CDC rRT-PCR Swine Flu Panel demonstrate inconclusive re-
sults that are positive for InfA and swH1 and negative for
swInfA.
A number of human clinical specimens received due to in-
conclusive results that were positive for InfA and swInfA but
negative for swH1 were subsequently confirmed as positive for
2009 A (H1N1) pdm influenza virus by bidirectional genetic
sequence analysis. Comparison of the nucleotide sequences of
the HA gene determined directly from clinical specimens con-
firmed three nucleotide mismatches within the probe region of
the swH1 assay (Fig. 3). However, a consistent pattern of
conserved nucleotide mutations whose circulation persisted
could not be identified. In fact, among the 7,122 HA genes of
2009 A (H1N1) pdm influenza viruses available from the
FIG. 2. CDC evaluation of inconclusive specimens (n  281) sub-
mitted by U.S. public health laboratories. Results obtained by the CDC
Influenza Division for 160 specimens with InfA CT values  30 and 121
specimens with CT values  30 confirmed by the CDC rRT-PCR Swine
Flu Panel and/or genetic sequence characterization are shown.
TABLE 5. Analytical specificity (inclusivity) testing with
swine influenza virusesa
Influenza virus Subtype
CT value for indicated assay
InfA swInfA swH1
Classical SIV
A/swine/Indiana/1726/1988 H1N1 20.10 22.41 24.31
A/Maryland/12/1991 H1N1 17.28 17.18 18.41
N. Am tr-SIV
A/Iowa/01/2006 H1N1 25.66 26.30 30.06
A/Illinois/09/2007 H1N1 31.22 31.51 31.11
A/Ohio/01/2007 H1N1 24.28 24.42 25.21
A/Missouri/04/2006 H1N1 19.97 19.58 22.18
A/Texas/14/2008 H1N1 22.12 22.04 23.45
A/Michigan/09/2007b H1N2 29.17 31.31 —c
A/Iowa/16/2009b H3N2 17.00 17.35 —
Eurasian SIV
A/swine/Italy/711/2006 H1N1 17.78 — —
a The tested viruses were isolated from swine as well as human cases of swine
origin influenza virus infection.
b H1N2 and H3N2 influenza viruses possessing HA and NA genes originating
from human seasonal influenza viruses.
c —, negative result.
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GISAID databases as of 30 August 2010, only 8 (0.11%) vi-
ruses with such genetic changes were identified.
DISCUSSION
The CDC rRT-PCR Swine Flu Panel is a highly sensitive and
specific assay for detection and characterization of N. Am
tr-SIV containing H1 HA subtype as well as 2009 A (H1N1)
pdm influenza viruses. The assay was shown to be highly sen-
sitive and detected as low as 101.01.6 ID50/ml of 2009 A
(H1N1) pdm or classical tr-SIV H1N1 viruses, which corre-
sponds to approximately 101.30.7 ID50 per reaction. Simi-
larly, the assay was shown to detect as few as 5 copies/reaction
of 2009 A (H1N1) pdm influenza virus RNA. Also, the CDC
rRT-PCR Swine Flu Panel was demonstrated to be highly
specific for characterization of N. Am SIV H1 subtype as well
as 2009 A (H1N1) pdm influenza viruses. As expected, all
tested classical SIV H1N1 and N. Am tr-SIV H1N1 viruses
were positive with all three assays, while tested N. Am tr-SIV
H1N2 and N. Am tr-SIV H3N2 viruses were InfA and swInfA
positive but swH1 negative, since both of the latter virus sub-
types possess HA antigens inherited from human seasonal
viruses (13, 14, 30).
The CDC rRT-PCR Swine Flu Panel did not show any
cross-reactivity among all three assays with common non-in-
fluenza A virus respiratory pathogens, influenza B cultured
viruses, or influenza B virus-positive clinical specimens. Cross-
reactivity was not observed in the swInfA and swH1 assays
used in testing human seasonal influenza A (H1N1 and H3N2)
viruses. No cross-reactivity was observed in the swH1 assay
when testing for highly pathogenic avian influenza (HPAI)
H5N1 viruses and other animal influenza viruses of different
subtypes. However, the swInfA assay demonstrated cross-re-
activity with HPAI H5N1 viruses and other non-SIV animal
influenza A viruses tested in this study due to similarities of
primer and probe sequences to those of some of these viruses.
Since none of the non-SIV animal influenza virus tested were
positive for all three assays on the CDC rRT-PCR Swine Flu
Panel, these results would be considered inconclusive and re-
quire further genetic analysis. Conclusive positive results were
not observed with a broad range of influenza viruses of non-
swine origin as well as with other respiratory pathogens, thus
demonstrating 100% analytical specificity of the CDC rRT-
PCR Swine Flu Panel.
Soon after the first confirmation (15 April 2009) of human
infection with 2009 influenza A (H1N1) pdm virus, the CDC
rRT-PCR Swine Flu Panel was cleared (27 April 2009) by the
U.S. Food and Drug Administration (FDA) with an Emer-
gency Use Authorization (EUA), and on 29 April 2009, testing
procedures were posted on the website of the World Health
Organization (WHO) (32). FDA clearance in 2008 (1) of the
CDC rRT-PCR Flu Panel, a diagnostic assay that utilizes iden-
tical procedures and instrumentation, facilitated expeditious
EUA clearance of the CDC rRT-PCR Swine Flu Panel. The
CDC rRT-PCR Flu Panel, including rRT-PCR primers,
probes, and controls, had been distributed since 2008 to sup-
port influenza surveillance and pandemic preparedness, allow-
ing public health laboratories to detect seasonal influenza A
(H1N1), A (H3N2), and HPAI A (H5N1) viruses (12). Ac-
cordingly, U.S. public health laboratories as well as many for-
eign laboratories have received training on use of the CDC
rRT-PCR Flu Panel. Rapid deployment of the CDC rRT-PCR
Swine Flu Panel to domestic and international laboratories
facilitated the timely detection of 2009 A (H1N1) pdm influ-
enza viruses, thus prompting state, local, and foreign govern-
ments to enact public health response activities. From 1 May
2009 until the declaration of the end of the emergency in the
United States (23 June 2010), more than 2,100 kits were dis-
tributed to hundreds of U.S. public health laboratories and
international National Influenza Centers (NICs).
It is well established that influenza viruses evolve rapidly and
are capable of adapting and generating diversity through ge-
netic mutation and genetic reassortment, particularly following
the emergence of a novel pandemic strain in humans (15, 16,
28). As the mutation rate and reassortment capabilities of the
2009 A (H1N1) pdm influenza viruses were initially unknown,
it was imperative to monitor the performance of the CDC
rRT-PCR Swine Flu Panel during the pandemic to determine
the effect of any genetic changes due to mutation or reassort-
ment that might affect assay performance. Therefore, U.S.
public health laboratories were advised to submit any clinical
specimens with inconclusive results to the CDC Influenza Di-
vision for further testing and characterization. Among those
submitted, six human specimens contained 2009 H1N1 LAIV,
giving positive test results by the InfA and swH1 assays but
negative results by the swInfA assay. This reactivity was ex-
pected, since the 2009 H1N1 LAIV is a reassortant virus that
contains six internal gene segments derived from the cold-
adapted master donor virus, A/Ann Arbor/6/1960 (H2N2), and
FIG. 3. Nucleotide sequence alignment of swH1 primer and probe regions from specimens and of viruses positive for 2009 A (H1N1) pdm
influenza virus that tested negative by the swH1 assay. Only locations where nucleotide differences were observed are indicated. The numbers of
specimens identified with each pattern of nucleic acid differences were as follows: for pattern 1, 19; for pattern 2, 2; for pattern 3, 1; for pattern
4, 1; for pattern 5, 1; for pattern 6, 1; and for pattern 7, 1. The primer and probe locations are indicated according to the HA gene coding domain
sequence of 2009 A (H1N1) pdm influenza virus strain A/California/07/2009 (FJ966974).
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the HA and NA gene segments from the recommended vac-
cine virus A/California/07/2009 (H1N1) pdm (5).
Genetic analysis of clinical specimens received during the
pandemic by the CDC due to inconclusive results obtained at
local laboratories revealed some viruses with various patterns
of three mutations in the binding region of the swH1 probe
that caused decreased reactivity of the swH1 assay. However,
viruses with similar mutations accounted for only 0.11% of
sequences submitted to the GISAID database as of September
2010, thus indicating that the vast majority of 2009 A (H1N1)
pdm influenza viruses were detectable by all three assays in the
CDC rRT-PCR Swine Flu Panel.
The CDC rRT-PCR Swine Flu Panel served as an effective
emergency tool throughout the pandemic for rapid detection
of 2009 A (H1N1) pdm virus in many countries and was es-
sential for emergency response implementation. Efforts to fur-
ther update and optimize procedures and reagents for detec-
tion of 2009 A (H1N1) pdm influenza viruses in human clinical
samples are still necessary in order to address the potential risk
of emerging variants with similar reactivity characteristics, as
well as to eliminate cross-reactivity of the swInfA assay with
avian and animal viruses.
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